SCM
IKT icon

Soleus Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Soleus Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Hold
10,875,000
– – 0.76% 37
2026
Q1 		$18.3M Hold
10,875,000
– – 0.74% 36
2025
Q4 		$22.3M Buy
10,875,000
+4,550,000
+72% +$7.24M 0.82% 38
2025
Q3 		$10.2M Hold
6,325,000
– – 0.52% 45
2025
Q2 		$12.3M Hold
6,325,000
– – 0.82% 34
2025
Q1 		$13.9M Hold
6,325,000
– – 1% 29
2024
Q4 		$20.6M Buy
+6,325,000
New +$15.8M 1.29% 23

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Soleus Capital Management's IKT Position: Q2 2026 in Review

Soleus Capital Management held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 10,875,000 shares worth $22.1M. The position accounts for 0.76% of the portfolio, ranked #37.

Soleus Capital Management first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $22.3M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Soleus Capital Management held 10,875,000 shares of Inhibikase Therapeutics worth $22.1M as of Q2 2026.
  • Soleus Capital Management left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up 0.76% of Soleus Capital Management's portfolio in Q2 2026, its #37 holding.
  • Soleus Capital Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Soleus Capital Management's Inhibikase Therapeutics position peaked at $22.3M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.